Arcadia Biosciences (NASDAQ:RKDA) Issues Quarterly Earnings Results, Misses Expectations By $1.31 EPS

Arcadia Biosciences (NASDAQ:RKDA) issued its earnings results on Thursday. The basic materials company reported ($2.11) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($1.31), FiscalAI reports. The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.60 million. Arcadia Biosciences had a negative net margin of 48.15% and a positive return on equity of 37.36%.

Arcadia Biosciences Stock Performance

RKDA stock traded up $0.01 during midday trading on Thursday, reaching $1.07. 140,032 shares of the company were exchanged, compared to its average volume of 31,949. Arcadia Biosciences has a 1-year low of $0.89 and a 1-year high of $6.71. The stock’s 50-day simple moving average is $1.42 and its 200 day simple moving average is $2.35. The company has a market cap of $2.20 million, a price-to-earnings ratio of -0.62 and a beta of 0.52.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Arcadia Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.